Drug profile · INN
pitavastatin sodium
NIKITA
pitavastatin sodium (NIKITA) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — pitavastatin sodium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pitavastatin sodium (NIKITA) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HMG-CoA reductase inhibitor
Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pitavastatin sodium?
pitavastatin sodium (NIKITA) is a hmg-coa reductase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for pitavastatin sodium?
NIKITA is a marketed brand name for pitavastatin sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pitavastatin sodium?
pitavastatin sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.